Mylan N.V. said its voard has unanimously rejected the unsolicited expression of interest from Teva Pharmaceutical Industries saying the offer grossly undervalued the company and that it has no interest in payment in "high-risk" Teva stock.
Article continues below
The Mylan Board concluded the approach did not meet any of the key criteria that would cause the Mylan board to depart from the company's successful and longstanding standalone strategy, and consider engaging in discussions to sell the company.
Mylan executive chairman Robert J. Coury commented, "Our Board has a very important fiduciary obligation to protect the best interests of the Company's shareholders and other stakeholders, and has always been open to considering all paths forward in that regard, and this situation is no different.
"However, that does not mean we will entertain offers that grossly undervalue the company, and leave our shareholders and other stakeholders exposed to serious risk.
"After thorough consideration, Mylan's Board unanimously determined that Teva's proposal grossly undervalues Mylan, and would require Mylan's shareholders to accept what we believe are low-quality Teva shares in exchange for their high-quality Mylan shares in a transaction that lacks industrial logic and carries significant global antitrust risk.
"In addition, we also believe that the proposal does not address the serious challenges of integrating two fundamentally different and conflicting cultures under a Teva Board and leadership team with a poor record of delivering sustainable shareholder value. We believe that these challenges would make it very difficult to generate value from this combination for Mylan shareholders.
"Furthermore, the proposal contains nothing meaningful indicating why a combination with Teva would be in the best interest of Mylan's employees, patients, customers, communities and other stakeholders.
"In summary, the Board determined that Teva's expression of interest is not in the best interests of Mylan, its shareholders or other stakeholders, and we believe that this is only a mere attempt by Teva to frustrate and distract Mylan from its business plan and strategy." ■